IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
Money will of course be no object when it comes to funding development of treatments for Covid-19, but how much exactly are we talking?
The industry has a duty to develop Covid-19 antivirals and vaccines, but the nature of clinical trials means that lower-profile measures must take precedence.
Having eschewed any late-stage moves in Nash, Novo Nordisk needs its established diabetes drug Ozempic to prove it has a place in the liver disease.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.